Suppr超能文献

分子和临床特征明确的儿童急性单核细胞白血病亚组的预后分层。

Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia.

机构信息

Division of Pediatric Blood Diseases Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.

出版信息

Cancer Med. 2020 Jun;9(11):3647-3655. doi: 10.1002/cam4.3023. Epub 2020 Mar 26.

Abstract

BACKGROUND

The prognosis of children with acute monocytic leukemia (AML-M5) remains unsatisfactory and the risk profile is still controversial. We aim to investigate the prognostic value of clinical and cytogenetic features and propose a new risk stratification in AML-M5 children.

METHODS

We included 132 children with AML-M5. Overall survival (OS) and progression-free survival (PFS) were documented. Cox regression was performed to evaluate the potential risk factors of prognosis.

RESULTS

The 5-year-OS was 46.0% (95% confidence intervals, 41.6%-50.4%) in all patients. There was significantly lower OS in the age ≤ 3 years old (P = .009) and hyperleukocytosis (P < .001). The FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) and MLL-rearrangement carriers were associated with fewer survivors in all patients (37.1% and 36.7%) and chemotherapy-only group (19.0% and 35.0%). Notably, the number of survivor with MLL-rearrangement did not increase in hematopoietic stem cell transplant (HSCT) group. According to the Cox regression analysis, HSCT was a significantly favorable factor (P = .001), while hyperleukocytosis, age ≤ 3 years old, and BM blast ≥ 70% adversely affected the OS in all patients (all P < .05). Additionally, FLT3-ITD was a risk factor for OS in the chemotherapy-only group (P = .023), while hyperleukocytosis and age ≤ 3 years independently contributed to poor PFS (both P < .05). In comparison to the standard-risk group, significant poorer outcome was found in the high-risk group (both P < .005).

CONCLUSIONS

We propose that AML-M5 children with any of MLL-rearrangement, FLT3-ITD, hyperleukocytosis, BM blast ≥ 70%, or age ≤ 3 years old are classified into the high-risk group, and HSCT is beneficial especially in patients with FLT3-ITD mutation, hyperleukocytosis, and age ≤ 3 years old. Importantly, the choice of HSCT should be made more carefully in children with MLL-rearrangement for its suboptimal performance.

摘要

背景

儿童急性单核细胞白血病(AML-M5)的预后仍不理想,风险分层仍存在争议。我们旨在探讨临床和细胞遗传学特征的预后价值,并提出一种新的 AML-M5 儿童风险分层方法。

方法

纳入 132 例 AML-M5 患儿。记录总生存(OS)和无进展生存(PFS)。采用 Cox 回归分析评估预后的潜在危险因素。

结果

所有患者的 5 年 OS 为 46.0%(95%置信区间,41.6%-50.4%)。年龄≤3 岁(P=0.009)和白细胞增多(P<0.001)患者的 OS 显著降低。FLT3 内部串联重复(ITD)和 MLL 重排携带者在所有患者(37.1%和 36.7%)和仅化疗组(19.0%和 35.0%)中幸存者比例较低。值得注意的是,在造血干细胞移植(HSCT)组中,MLL 重排患者的幸存者数量并未增加。根据 Cox 回归分析,HSCT 是一个显著有利的因素(P=0.001),而白细胞增多、年龄≤3 岁和骨髓原始细胞≥70%均对所有患者的 OS 产生不良影响(均 P<0.05)。此外,FLT3-ITD 是仅化疗组 OS 的危险因素(P=0.023),而白细胞增多和年龄≤3 岁独立导致较差的 PFS(均 P<0.05)。与标准风险组相比,高危组的结局明显较差(均 P<0.005)。

结论

我们提出,任何 MLL 重排、FLT3-ITD、白细胞增多、骨髓原始细胞≥70%或年龄≤3 岁的 AML-M5 患儿均归入高危组,HSCT 特别有利于 FLT3-ITD 突变、白细胞增多和年龄≤3 岁的患者。重要的是,由于 MLL 重排患儿的表现不佳,应更谨慎地选择 HSCT。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4835/7286455/8f41de6a9ff8/CAM4-9-3647-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验